In re Appln. of Flack et al. Serial No. 08/379,872

J' ent

gossypolone, and a pharmaceutically acceptable carrier[, wherein administration of said anti-cancer effective amount of said compound results in a blood concentration of said compound of 200-1000 ng/dl].

(Thrice Amended) A method for treating a cancer in a human, wherein the cancer is susceptible to treatment with gossypol, a pharmaceutically acceptable salt of gossypol, or a combination thereof, which method comprises:

12

administering to said human an anti-cancer effective amount of at least one compound selected from the group consisting of gossypol and a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier[, wherein administration of said anti-cancer effective amount of said compound results in a blood concentration of said compound of 200-1000 ng/dl].

REMARKS

The Present Invention

The present invention is directed to a method of treating a cancer in a human wherein the cancer is susceptible to treatment with gossypol, a pharmaceutically acceptable salt of gossypol, gossypolone, a pharmaceutically acceptable salt of gossypolone, or any combination thereof. The method comprises administering to the human an anti-cancer effective amount of one or more of these compounds in a pharmaceutically acceptable carrier.